The Application of Glucose CEST MR Imaging in Brain Tumor

Study Overview
=================
Brief Summary
-----------------
Recently, natural D-glucose was suggested as a potential biodegradable contrast agent. The feasibility of using D-glucose for dynamic perfusion imaging was explored to detect malignant brain tumors based on blood brain barrier breakdown. Our study try to evaluate the feasibility of dynamic glucose enhanced(DGE) magnetic resonance imaging（MRI）in brain tumor, which based on D-glucose weighted chemical exchange saturation transfer (gluceoCEST).

Detailed Description
-----------------
methods： Brain tumor patients were recruited. Time-resolved glucose signal changes were detected using chemical exchange saturation transfer (glucoCEST) MRI. Dynamic glucose enhanced (DGE) MRI was used to measure tissue response to an intravenous bolus of D-glucose. During the dynamic glucose scan, a brief hyperglycemic state was established by intravenous infusion of hospital-grade D50 glucose (D50, 25 g of dextrose in 50 mL of water sterile solution), followed by 20 mL of saline solution in 1 arm. The glucose infusion was performed using a power injector at an infusion rate of 0.2 mL/s, corresponding to total infusion times of 250 seconds. Performing contrast enhancement based on Gd-DTPA in 30 minutes later, which was used for comparison as golden standard. The area of hyperintensity will be measured, which represents the area of brain tumor. Differential test and Consistency analysis were used for statistical analysis.

Official Title
-----------------
The Evaluation of D-glucose Weighted Chemical Exchange Saturation Transfer (gluceoCEST)-Based Dynamic Glucose Enhanced(DGE) Magnetic Resonance Imaging（MRI） in Brain Tumor

Conditions
-----------------
Magnetic Resonance Imaging

Intervention / Treatment
-----------------
* Drug: d-glucose


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient must have a brain mass consistent with a primary brain tumor or metastatic brain tumor able to give consent and willingness to participate in this study. Exclusion Criteria: presence of any ferromagnetic implant (cardiac pacemakers, aneurysm clip, etc.) pregnancy claustrophobia or anxiety disorder history of vertigo persons with diabetes mellitus (self-report or HbA1C >= 6.5%) Sickle cell disease persons taking prescription medicine for hypertension blood iron deficiency (Hb concentration < 11 g/dL or Hct < 32%) If volunteering for MRI: history of kidney disease and/or eGFR < 60. Middle-ear disorder double vision Seizure disorder Multiple myeloma Solid organ transplant History of severe hepatic disease/liver transplant/pending liver transplant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: D-glucose<br>During the dynamic glucose scan, a brief hyperglycemic state was established by intravenous infusion of hospital-grade D50 glucose (D50, 25 g of dextrose in 50 mL of water sterile solution), followed by 20 mL of saline solution in 1 arm. The glucose infusion was performed using a power injector at an infusion rate of 0.2 mL/s, corresponding to total infusion times 250 seconds. | Drug: d-glucose<br>* using d-glucose as an contrast agent on CEST MR Imaging<br>* Other names: 50% dextrose injection;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CEST value of tumor lesion including tumor core/ necrosis/ cysis/ edema | the CEST value of tumor core and necrosis might higher than white matter | 1 week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dynamic glucose enhanced, human brain tumor, chemical exchange saturation transfer